Notably, encapsulation of AMD3100 and anti-angiogenic substance VEGF siRNA into lipid-based NPs formulations targeting CXCR4, namely AMD-NPs, could effectively deliver VEGF siRNAs into HCC and down-regulate VEGF expression in vitro and in vivo. This evidence concerns the gene CXCR4 and hepatocellular carcinoma.